Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P38567
UPID:
HYALP_HUMAN
Alternative names:
Hyaluronoglucosaminidase PH-20; Sperm adhesion molecule 1; Sperm surface protein PH-20
Alternative UPACC:
P38567; Q8TC30
Background:
Hyaluronidase PH-20, also known as Sperm adhesion molecule 1 or Sperm surface protein PH-20, plays a crucial role in fertilization. It aids sperm in penetrating the cumulus cells surrounding the egg by digesting hyaluronic acid, a major component of the matrix embedding these cells. This process is vital for successful sperm-egg adhesion and subsequent fertilization.
Therapeutic significance:
Understanding the role of Hyaluronidase PH-20 could open doors to potential therapeutic strategies. Its unique function in sperm-egg adhesion presents opportunities for developing innovative fertility treatments and contraceptives.